CFTR and sarcopenia: Promising data achieved presently by local administration of either CFTR‐containing virus or VX809 in aged wild‐type mice have confirmed the potential of enhancing CFTR as a new therapeutic strategy for sarcopenia or other skeletal muscle disorders in a general population.